ClinicalTrials.gg
CompletedNCT02294773Updated Dec 9, 2015Results posted

Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit

An interventional study of Intrauterine Insemination and Clomiphene in Infertility, sponsored by Midwest Fertility Specialists. Completed at 2 sites in United States. Open to female participants aged 21 Years to 39 Years. Per ClinicalTrials.gov, last updated 2015-12-09.

Sponsored by Midwest Fertility Specialists · Not applicable and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
21 Years to 39 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing clomiphene in Infertility — 1 open to participants now, 4 under way, 1 of them phase 3. Clomiphene · Infertility.

Enrollment
29th of 33
13 · median 154
Started
2013
the only one that year
No phase
7 of 33
none open now
Registered
20th of 33
by date

Among the 33 studies testing clomiphene in Infertility, this one is the 29th largest by enrollment, is the only one that started in 2013, is one of 7 with no phase, and was the 20th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 33 studies testing clomiphene in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About clomiphene

Clomiphene: first FDA approval 1967 (CLOMID). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 21 Years to 39 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing clomiphene in Infertility, or all of them as a file.
02

Study summary

The aim of this study is to assess the impact of the timing of intrauterine insemination (IUI) in relation to the natural surge of luteinizing hormone (LH), as detected by home ovulation predictor kits, on pregnancy rates per treatment cycle. The study will take place at the offices of Midwest Fertility Specialists and include patients who have been independently recommended by their primary physician to undergo ovulation induction with clomiphene citrate (CC) or letrozole and IUI as therapy for infertility.

Read the detailed description

Intrauterine insemination is a procedure that is performed in the physician's office. During the procedure the sperm from the male partner are placed directly into the female partner's uterus around the time of ovulation (release of oocyte or egg). Ovulation predictor kits, available over the counter at pharmacies, test for the presence of luteinizing hormone in the urine. When the test result is a positive, it means the hormone is present in the urine. This is a sign of ovulation. Physicians typically choose to perform intrauterine insemination either the day of a positive ovulation test or the day after a positive ovulation test. The purpose of this study is to determine if the day when intrauterine insemination is performed influences the chance of becoming pregnant.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Infertility
  • Intrauterine insemination
  • Luteinizing hormone surge
04

Who can participate

Ages eligible
21 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All couples consisting of male and female partner undergoing CC or letrozole cycle plus IUI at a single infertility center (Midwest Fertility Specialists)
  • The female partner must be aged 21-39
  • Infertile couples include those with a diagnosis(s) of unexplained infertility, mild male factor, ovulatory dysfunction, or anovulation
  • Evidence of a normal uterus and at least unilateral tubal patency on saline infusion sonogram or hysterosalpingogram within the last 2 years
  • Semen analysis for male partner must have minimal sperm concentration of 10 million per milliliter

Exclusion criteria

Exclusion Criteria:

  • Recurrent miscarriages
  • Nursing mothers
  • Diagnoses of primary ovarian failure, diminishing ovarian reserve (as indicated by blood follicle stimulating hormone >10 milliInternationalUnits/mL and/or anti-mullerian hormone level \<0.5), abnormal uterine bleeding of undetermined origin, ovarian cyst of undetermined origin, stage IV endometriosis, or sex-hormone dependent tumors
  • Documented bilateral tubal obstruction or other uncorrected uterine anomalies (e.g. uterine septum)
  • Previous gonadotropin use and/or previous treatment with in vitro fertilization
  • Abnormal semen analysis (sperm concentration less than 10 million per mL) or ejaculatory dysfunction in male partner
  • Other uncorrected medical condition in female partner that would be a to attempting elective ovulation induction (e.g., uncontrolled diabetes, intracranial lesion, thyroid or adrenal disease)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    Day Of

    This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day the home ovulation predictor kit first turns positive.

    Procedure: Intrauterine Insemination · Drug: Clomiphene · Drug: Letrozole

  • Active comparator
    Day After

    This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day after the home ovulation predictor kit first turns positive.

    Procedure: Intrauterine Insemination · Drug: Clomiphene · Drug: Letrozole

Interventions

  • ProcedureIntrauterine Insemination

    Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.

  • Patient is to take clomiphene citrate during cycle days 3-7.

    Also known as: clomid

  • Patient is to take letrozole during cycle days 3-7.

06

What researchers measure

Primary outcomes

  1. Number of Pregnancies Achieved Per Menstrual Cycle.

    Time frame: Up to 3 months

Other outcomes

  1. Per Cycle Pregnancy Rate Based on Infertility Diagnosis

    Time frame: Up to cycle day 35

  2. Pregnancy Rate Per Female Partner Age

    Pregnancy rate will be compared between patients \<35 and \>35 at time of study entry.

    Time frame: Up to cycle day 35

  3. Pregnancy Rate Per Semen Morphology Score

    Comparison of pregnancy rate based on semen morphology of \<4% vs \>4% normal morphology scores.

    Time frame: Up to cycle day 35

  4. Pregnancy Rate Per Body Mass Index Category

    Time frame: Up to cycle day 35

07

Results

Posted Dec 9, 2015

Participant flow

Patients recruited from two clinical offices from 1/2014 until 9/2015.

Participant flow — Overall Study
MilestoneInsemination Day Of Positive OPKInsemination Day After Positive OPK
Started76
Completed74
Not completed02
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryNumber of Pregnancies Achieved Per Menstrual Cycle.
Time frame:
Up to 3 months
Reported as:
Number · pregnancies per cycle
Number of Pregnancies Achieved Per Menstrual Cycle.
pregnancies per cycleInsemination Day Of Positive OPKInsemination Day After Positive OPK
Number of Pregnancies Achieved Per Menstrual Cycle.00
Other pre-specifiedPer Cycle Pregnancy Rate Based on Infertility Diagnosis
Time frame:
Up to cycle day 35
Reported as:
Number · pregnancies per cycle
Per Cycle Pregnancy Rate Based on Infertility Diagnosis
pregnancies per cycleInsemination Day Of Positive OPKInsemination Day After Positive OPK
Per Cycle Pregnancy Rate Based on Infertility Diagnosis00
Other pre-specifiedPregnancy Rate Per Female Partner Age

Pregnancy rate will be compared between patients \<35 and \>35 at time of study entry.

Time frame:
Up to cycle day 35
Reported as:
Number · pregnancies per cycle
Pregnancy Rate Per Female Partner Age
pregnancies per cycleInsemination Day Of Positive OPKInsemination Day After Positive OPK
Female age < 3500
Female age > 3500
Other pre-specifiedPregnancy Rate Per Semen Morphology Score

Comparison of pregnancy rate based on semen morphology of \<4% vs \>4% normal morphology scores.

Time frame:
Up to cycle day 35
Reported as:
Number · pregnancies per cycle
Pregnancy Rate Per Semen Morphology Score
pregnancies per cycleInsemination Day Of Positive OPKInsemination Day After Positive OPK
Semen morphology < 4%00
Semen morphology > 4%00
Other pre-specifiedPregnancy Rate Per Body Mass Index Category
Time frame:
Up to cycle day 35
Reported as:
Number · pregnancies per cycle
Pregnancy Rate Per Body Mass Index Category
pregnancies per cycleInsemination Day Of Positive OPKInsemination Day After Positive OPK
Body mass index normal00
Body mass index overweight00
Body mass index obese00

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insemination Day Of Positive OPK—0/7 (0%)0/7 (0%)
Insemination Day After Positive OPK—0/6 (0%)0/6 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Insemination Day Of Positive OPKInsemination Day After Positive OPKTotal
Mean30.4 ± 5.929.6 ± 3.0530.1 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)Insemination Day Of Positive OPKInsemination Day After Positive OPKTotal
Female7613
Male000
Region of Enrollment
Region of Enrollment(participants)Insemination Day Of Positive OPKInsemination Day After Positive OPKTotal
United States7613
Body Mass Index
Body Mass Index(kg/m^2)Insemination Day Of Positive OPKInsemination Day After Positive OPKTotal
Mean30 ± 8.925 ± 427.9 ± 7.5
Day 3 Follicle Stimulating Hormone
Day 3 Follicle Stimulating Hormone(mIU/ml)Insemination Day Of Positive OPKInsemination Day After Positive OPKTotal
Mean7.6 ± 1.76.2 ± 1.96.9 ± 1.8
Anti-mullerian Hormone
Anti-mullerian Hormone(ng/ml)Insemination Day Of Positive OPKInsemination Day After Positive OPKTotal
Mean3.1 ± 2.25.8 ± 05.2 ± 2.3
Sperm Concentration
Sperm Concentration(million sperm/ml)Insemination Day Of Positive OPKInsemination Day After Positive OPKTotal
Mean32.6 ± 13.971.2 ± 39.239.4 ± 30.9
Sperm morphology
Sperm morphology(Percent normal)Insemination Day Of Positive OPKInsemination Day After Positive OPKTotal
Mean5.6 ± 2.38.5 ± 2.46.2 ± 2.6

1 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Midwest Fertility Specialists- Fort Wayne
    Fort Wayne, Indiana 46825, United States
  • Midwest Fertility Specialists
    Indianapolis, Indiana 46032, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2014
First posted
Nov 19, 2014
Start
Oct 2013
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Dec 9, 2015
Last update
Dec 9, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02294773
Lead sponsor
Midwest Fertility Specialists
Responsible party
Sponsor
First posted
Nov 19, 2014
Start date
Oct 2013
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Dec 9, 2015
Last update
Dec 9, 2015

Study contacts

Matthew Will, MD
principal investigator · Midwest Fertility Specialists

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clomiphene · Letrozole

Start the discussion